TI
SPRY icon

Trexquant Investment’s ARS Pharmaceuticals SPRY Stock Holding History

Trexquant Investment’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
+286,733
New +$2.47M 0.01% 1137
2026
Q1 		– Sell
-150,100
Closed -$1.75M – 2036
2025
Q4 		$1.75M Sell
150,100
-481,620
-76% -$4.68M 0.02% 1037
2025
Q3 		$6.35M Buy
+631,720
New +$9.07M 0.07% 450
2025
Q2 		– Sell
-100,769
Closed -$1.27M – 1856
2025
Q1 		$1.27M Buy
100,769
+44,206
+78% +$532K 0.01% 1019
2024
Q4 		$597K Sell
56,563
-28,732
-34% -$402K 0.01% 1237
2024
Q3 		$1.24M Buy
+85,295
New +$1.01M 0.02% 976
2024
Q2 		– Sell
-27,120
Closed -$277K – 1833
2024
Q1 		$277K Buy
+27,120
New +$202K 0.01% 1306
2022
Q1 		– Sell
-30,498
Closed -$203K – 1704
2021
Q4 		$203K Sell
30,498
-14,718
-33% -$120K 0.01% 1146
2021
Q3 		$451K Buy
+45,216
New +$1.12M 0.04% 579

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Trexquant Investment's SPRY Position: Q2 2026 in Review

Trexquant Investment opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 286,733 shares worth $2.3M. The stake represents 0.01% of the portfolio and ranks #1137 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in SPRY as recently as Q4 2025.

Trexquant Investment first reported a position in SPRY in Q3 2021 and has held it in 9 quarters since. The position peaked at $6.35M in Q3 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Trexquant Investment held 286,733 shares of ARS Pharmaceuticals worth $2.3M as of Q2 2026.
  • ARS Pharmaceuticals was a new Trexquant Investment position in Q2 2026.
  • ARS Pharmaceuticals made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1137 holding.
  • Trexquant Investment first reported a position in ARS Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
  • Trexquant Investment's ARS Pharmaceuticals position peaked at $6.35M in Q3 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.